Differences in tumor-to-normal organ SUV ratios measured with 68Ga-DOTATATE PET compared with 177Lu-DOTATATE SPECT in patients with neuroendocrine tumors

被引:5
|
作者
Wong, Ka Kit [1 ]
Frey, Kirk A. [1 ]
Niedbala, Jeremy [1 ]
Kaza, Ravi K. [1 ]
Worden, Francis P. [2 ]
Fitzpatrick, Kellen J. [1 ]
Dewaraja, Yuni K. [1 ]
机构
[1] Univ Michigan, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Endocrine Oncol, Ann Arbor, MI 48109 USA
关键词
Ga-68-DOTATATE; Lu-177-DOTATATE; neuroendocrine tumor; PET/CT; peptide receptor radionuclide therapy; SPECT/CT; SUV; theranostics; RECEPTOR RADIONUCLIDE THERAPY; SST1-SST5; DOSIMETRY; SUBTYPES; PRRT;
D O I
10.1097/MNM.0000000000001592
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Background Our goal is to quantitatively compare radiotracer biodistributions within tumors and major normal organs on pretherapy Ga-68-DOTATATE PET to post-therapy Lu-177-DOTATATE single-photon emission computed tomography (SPECT) in patients receiving peptide receptor radionuclide therapy (PRRT). Methods PET/CT at similar to 60 min postinjection of Ga-68 DOTATATE and research Lu-177-SPECT/CT imaging similar to at 4h (SPECT1) and similar to 24h (SPECT2) post-cycle#1 were available. Manual contours of lesions on baseline CT or MRI were applied to co-registered SPECT/CT and PET/CT followed by deep learning-based CT auto-segmentation of organs. Tumor-to-normal organ ratios (TNR) were calculated from standardized uptake values (SUV)(mean) and SUVpeak for tumor, and SUVmean for non-tumoral liver (nliver), spleen and kidney. Results There were 90 lesons in 24 patients with progressive metastatic neuroendocrine tumor. The correlation between PET and SPECT SUV TNRs were poor/moderate: PET versus SPECT1 R-2 =0.19. 0.21, 0.29; PET versus SPECT2 R-2 =0.06, 0.16, 0.33 for TNRnliver,TNRspleen, TNRkidney, respectively. Across all patients, the average value of the TNR measured on PET was significantly lower than on SPECT at both time points (P<0.001). Using SUVmean for tumor, average TNR values and 95% confidence intervals (CI) were PET: TNRnliver =3.5 [CI: 3.0-3.9], TNRspleen =1.3 [CI. 1.2-1.5], TNRkidney = 1.7 [CI: 1.6-1.9]; SPECT1: TNRnliver = 1.0 [CI: 8.2-11.7], TNRspleen = 2.9 [CI: 2.5-3.4]. TNRkidney = 2.8 [CI: 2.3-3.3]; SPECT2: TNRnliver = 1 6.9 [CI: 1 4-1 9.9], TNRspleen =3.6 [CI: 3-4.2], TNRkidney = 3.6 [CI: 3.0-4.2]. Comparison of PET and SPECT results in a sphere phantom study demonstrated that these differences are not attributed to imaging modality. Conclusions Differences in TNR exist for the theranostic pair, with significantly higher SUV TNR on Lu-177 SPECT compared with Ga-68 PET. We postulate this phenomenon is due to temporal differences in DOTATATE uptake and internalization in tumor as compared to normal organs. (C) 2022 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码:892 / 900
页数:9
相关论文
共 50 条
  • [41] 68Ga-DOTATATE PET/CT Findings of Cervical Esophageal Neuroendocrine Tumor
    Filizoglu, Nuh
    Ozguven, Salih
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (07) : E393 - E394
  • [42] Primary Neuroendocrine Tumor of the Ileostomy Stoma on 68Ga-DOTATATE PET/CT
    Yu, Lei
    Braun, Alexander
    Hansen, Neil J.
    Downey, Ryan T.
    Johnson, Craig M.
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (06) : 463 - 464
  • [43] Estimation of tumor burden from 68Ga- Dotatate-PET/CT and day-7 planar 177Lu images, for patients treated with 177Lu-Dotatate
    Gleisner, K. Sjogreen
    Gustafsson, J.
    Stenvall, A.
    Roth, D.
    Hindorf, C.
    Jonsson, L.
    Larsson, E.
    Olsson, T.
    Sundlov, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S376 - S377
  • [44] Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT
    Hoberueck, Sebastian
    Michler, Enrico
    Zoephel, Klaus
    Platzek, Ivan
    Kotzerke, Joerg
    Brogsitter, Claudia
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (01) : 50 - 52
  • [45] A reassessment of the clinical utility of 68Ga-DOTATATE PET/CT in patients with gastroenteropancreatic neuroendocrine tumors
    Prela, Orjola
    Caveney, Brennen
    Strawderman, Myla S.
    Carpizo, Darren R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [46] Utility of 68Ga-DOTANOC PET/CT for response assessment in neuroendocrine tumours treated with 177Lu-DOTATATE
    Satapathy, Swayamjeet
    Sood, Ashwani
    Sood, Apurva
    Mittal, Bhagwant
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
  • [47] Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors A Feasibility Study
    Thuillier, Philippe
    Maajem, Meriem
    Schick, Ulrike
    Blanc-Beguin, Frederique
    Hennebicq, Simon
    Metges, Jean-Philippe
    Salaun, Pierre-Yves
    Kerlan, Veronique
    Bourhis, David
    Abgral, Ronan
    CLINICAL NUCLEAR MEDICINE, 2021, 46 (02) : 111 - 118
  • [48] The Influence of 68Ga-DOTATATE PET/CT Imaging in the Management Decision of Patients with Neuroendocrine Tumors
    Skoura, E.
    AlMukhalid, O. M.
    Panagiotidis, E.
    Al Harbi, M.
    Kayani, I.
    Michopoulou, S.
    Syed, R.
    Ell, P. J.
    Caplin, M. E.
    Bomanji, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2015, 42 : S230 - S231
  • [49] Testicular Metastasis From Neuroendocrine Tumors: Imaging and Theranostics Through 68Ga-DOTATATE PET/CT and 177Lu-DOTATATE-Based Peptide Receptor Radionuclide Therapy
    Parghane, Rahul V.
    Basu, Sandip
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (12) : 1051 - 1052
  • [50] First outcomes from OZM-067-a multicenter single arm study of 177Lu-DOTATATE therapy for primary site agnostic 68Ga-DOTATATE PET positive progressive metastatic neuroendocrine tumors
    Wong, Rebecca
    Laidley, David
    Myrehaug, Sten
    Juergens, Rosalyn
    Metser, Ur
    Ezzat, Shereen
    Yeung, Ivan
    Driscoll, Brandon
    Gabrys, Judy
    Publicover, Julia
    Shessel, Andrea
    Levine, Oren
    Veit-Haibach, Patrick
    Mohan, Ravi
    Breen, Stephen
    Zukotynski, Katherine
    Mesci, Aruz
    Brierley, James
    Lajkosz, Katherine
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65